| Description | Vazegepant hydrochloride (Vazegepant HCl) is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study. |
| Target activity | CGRP (human):0.023 nM (Ki) |
| Synonyms | Vazegepant HCl |
| molecular weight | 675.3 |
| Molecular formula | C36H47ClN8O3 |
| CAS | 1414976-20-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 30 mg/mL (44.43 mM) |
| References | 1. Moreno-Ajona D , Abigail Pérez-Rodríguez, Goadsby P J . Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?[J]. Current Opinion in Neurology, 2020, 33(3):1. |